Form 4: Director Buchi Transfers Benitec Biopharma Shares

Director J. Kevin Buchi reported a disposition of 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised charitable fund.

Summary

• J. Kevin Buchi, a Director at Benitec Biopharma Inc., reported a transaction on June 29, 2026.
• The transaction involved the transfer of 51,813 shares of common stock.
• These shares were transferred to a donor-advised fund sponsored by a charitable organization.
• The transfer was made under Section 501(c)(3) of the Internal Revenue Code.
• Following this transaction, Mr. Buchi beneficially owns 52,097 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a charitable donation by a director rather than a sale driven by financial performance or strategic concerns.

Positives

• Director J. Kevin Buchi made a charitable contribution of company stock.
• The transfer was to a donor-advised fund, indicating a philanthropic action.

Negatives

• A significant number of shares (51,813) were transferred out of direct beneficial ownership by a director.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, such as this charitable transfer by a director. These filings provide transparency into the holdings and activities of company insiders.

Stakeholder Impact

• Shareholders: The transfer does not directly impact the company's financial health but reflects a director's personal philanthropic decision. The remaining direct beneficial ownership by the director is still substantial.

Key Dates

Keywords

Benitec Biopharma, BNTC, Form 4, Insider Transaction, Director, Charitable Donation, Stock Transfer